Studies selection process
At the initial, 458 articles were retrieved from the database searching, 307 of which remained after duplicates removed. After removing meeting abstract, editorial material and letters, 292 articles were obtained. Of these, 209 were excluded since they did not meet the inclusion criteria. After full text articles assessed for eligibility, another 18 articles were excluded. Finally, 65 articles with 338 cases were enrolled in this systematic review for further data extraction. The flow chart shown in Figure.1 demonstrates the selection process in detail.
Study characteristics
Baseline characteristics are showed in Table 1. All the enrolled studies were case report and case series with the case number ranged from 1 to 107 patients. Kyvernitakis[1] reported the most cases numbered at 107 based on the German reference center for PLO and Laroche[2] reported the subsequent most cases numbered at 52 based on the French Society of Rheumatology. The number of articles published increased year by year, with 9 articles from 1991 to 2000, 13 articles from 2001 to 2010, and 43 articles from 2011 to 2020. The enrolled studies distributed globally with 34 studies in Europe, 17 studies in Asia, 5 studies in Australia, 5 studies in South America, 3 studies in North America and one study in Africa. Turkey had the highest number of PLO articles which 11 articles were recorded, followed by Germany with 8 articles and Italy (n = 7) and South Korea (n = 7).
Table 1
The enrolled studies and baseline characteristics of the enrolled cases
|
Number
|
First author
|
Location
|
Published year
|
Journal
|
No of Cases
|
Race
|
Age at onset(years)
|
Height(cm)
|
Weight(kg)
|
BMI(kg/m2)
|
1
|
Tuna
|
Turkey
|
2020
|
Gynecol Endocrinol
|
9/14
|
|
31
|
|
|
21.3
|
2
|
Hardcastle
|
UK
|
2019
|
Osteoporos Int
|
10
|
1Moroccan
|
33
|
|
|
23.3
|
3
|
Scott
|
Australia
|
2019
|
Osteoporos Int
|
1
|
Caucasian
|
33
|
162
|
74
|
28.2
|
4
|
Ozturk
|
Turkey
|
2019
|
Gynecol Endocrinol
|
2
|
|
33,28
|
|
|
27.4,22.6
|
5
|
Gehlen
|
Germany
|
2019
|
Clin Rheumatol
|
20
|
|
33.9(27-42)
|
|
|
23.5(16.9-39)
|
6
|
Zhu
|
Australia
|
2018
|
Osteoporos Int
|
2
|
|
29
|
|
|
|
7
|
Li
|
China
|
2018
|
Clin Rheumatol
|
10/12
|
9Han,1Manchu
|
31
|
|
|
21.5
|
8
|
Hong
|
Korea
|
2018
|
Clin Endocrinol
|
32
|
|
31.3 ± 2.6
|
|
|
20.3±2.4
|
9
|
Butscheidt
|
Germany
|
2018
|
Osteoporos Int
|
5/7
|
|
35
|
|
|
22.8
|
10
|
Taraktas
|
Italy
|
2018
|
Turk J Endocrinol Metab
|
1
|
|
22
|
|
|
|
11
|
Yun
|
Korea
|
2017
|
Obstet Gynecol Sci
|
6
|
|
32
|
164
|
57
|
21.1
|
12
|
Kyvernitakis
|
Germany
|
2017
|
Osteoporos Int
|
107
|
|
39.5+-6.0
|
165.9+/-6.3;
|
63.5+/-11.1
|
23.1±3.7
|
13
|
Zhang
|
China
|
2017
|
Medicine
|
1
|
|
23
|
|
|
21.2
|
14
|
Laroche
|
France
|
2017
|
Osteoporos Int
|
52
|
|
27
|
|
|
|
15
|
Ljuin
|
Japan
|
2017
|
Taiwan J Obstet Gynecol
|
1
|
|
27
|
163
|
45
|
17.1
|
16
|
Pola
|
Italy
|
2016
|
J Biol Regul Homeost Agents
|
1
|
Caucasian
|
33
|
167
|
60
|
21.5
|
17
|
Krishnakumar
|
India
|
2016
|
J Craniovert Jun Spine
|
2
|
|
27,31
|
|
|
|
18
|
Sánchez
|
Argentina
|
2016
|
Clin Cases Miner Bone Metab
|
2
|
|
35,33
|
162157
|
|
|
19
|
Grana
|
Italy
|
2016
|
Pain Med
|
1
|
Caucasian
|
31
|
|
|
|
20
|
Gaudio
|
Italy
|
2016
|
Clin Cases Miner Bone Metab
|
1
|
|
38
|
167
|
54
|
19.4
|
21
|
Ekim
|
Turkey
|
2016
|
J Clin Anal Med
|
1
|
|
35
|
165
|
54
|
19.8
|
22
|
Polat
|
Turkey
|
2015
|
Gynecol Endocrinol
|
1
|
|
23
|
|
|
24.0
|
23
|
Hadgaonkar
|
India
|
2015
|
Asian Spine J
|
1
|
|
24
|
|
|
|
24
|
Ozdemir
|
Turkey
|
2015
|
Osteoporos Int
|
2
|
|
34,36
|
168, 162
|
62,59
|
21.9,22.5
|
25
|
Kovacs
|
Canada
|
2015
|
Osteoporos Int
|
1/2
|
|
35
|
151
|
46
|
20.0
|
26
|
Grizzo
|
Brazil
|
2015
|
Calcif Tissue Int
|
1
|
Caucasian
|
31
|
165
|
55
|
20.2
|
27
|
Zarattini
|
Italy
|
2014
|
Clin Cases Miner Bone Metab
|
1
|
Caucasian
|
27
|
165
|
63
|
23.1
|
28
|
Takahashi
|
Japan
|
2014
|
Fukushima J Med Sci
|
1
|
|
22
|
163
|
60
|
22.6
|
29
|
Obando
|
Netherlands
|
2014
|
J Clin Endocrinol Metab
|
1
|
Caucasian
|
27
|
158
|
53
|
21.2
|
30
|
Raffaetà
|
Italy
|
2014
|
Clin Cases Miner Bone Metab
|
2
|
|
42,21
|
167
|
66
|
23.7
|
31
|
Ozturk
|
Turkey
|
2014
|
J Obstet Gynaecol
|
2
|
|
22,34
|
|
|
|
32
|
Baldane
|
Turkey
|
2014
|
Turk Fiz Tip Rehabil Derg
|
1
|
|
35
|
155
|
45
|
18.7
|
33
|
Winarno
|
Germany
|
2014
|
Z Geburtsh Neonatol
|
1
|
|
29
|
158
|
46
|
18.4
|
34
|
Terzi
|
Turkey
|
2014
|
BioMed Res Int
|
1
|
|
32
|
|
|
|
35
|
Cook
|
USA
|
2014
|
J Bone Miner Res
|
1
|
Caucasian
|
26
|
161
|
68
|
26.2
|
36
|
Scozzari
|
Italy
|
2014
|
Acta Medica Mediterranea
|
1
|
|
19
|
|
|
|
37
|
Lee
|
Korea
|
2013
|
J Bone Metab
|
1
|
|
39
|
156
|
50
|
20.5
|
38
|
Bonacker
|
Germany
|
2013
|
Arch Orthop Trauma Surg
|
1
|
|
40
|
|
|
|
39
|
Lwamoto
|
Japan
|
2012
|
Ther Clin Risk Manag
|
1
|
|
32
|
155
|
57
|
23.7
|
40
|
Adamidou
|
Greece
|
2012
|
Horm-Int J Endocrinol Metab
|
1
|
Caucasian
|
40
|
158
|
56
|
22.4
|
41
|
Choe
|
Korea
|
2012
|
J Bone Miner Metab
|
3
|
|
36,32,30
|
|
|
20.6,27.1,19.4
|
42
|
Stupar
|
Serbia
|
2012
|
Rheumatol Int
|
1
|
|
30
|
152
|
52
|
22.5
|
43
|
Lee
|
Korea
|
2011
|
J Back Musculoskelet Rehabil
|
1
|
|
31
|
157
|
50
|
20.3
|
44
|
Mastaglia
|
Argentina
|
2010
|
Osteoporos Int
|
1
|
|
20
|
|
|
|
45
|
Kim
|
Korea
|
2010
|
J Korean Neurosurg Soc
|
1
|
|
35
|
150
|
42
|
18.7
|
46
|
Hellmeyer
|
Germany
|
2010
|
Gynecol Endocrinol
|
1
|
|
40
|
171
|
62
|
21.2
|
47
|
Tanriover
|
Turkey
|
2009
|
Spine J
|
1
|
Caucasian
|
23
|
169
|
65
|
22.8
|
48
|
Jang
|
Korea
|
2009
|
Rheumatol Int
|
1
|
|
30
|
163
|
52
|
19.6
|
49
|
Ofluoglu
|
Turkey
|
2008
|
Rheumatol Int
|
1
|
|
30
|
162
|
50
|
19.1
|
50
|
Stumpf
|
Germany
|
2007
|
Adv Med Sci
|
2
|
|
32,41
|
|
|
19.0
|
51
|
Hellmeyer
|
Germany
|
2007
|
Exp Clin Endocrinol Diabet
|
1
|
|
28
|
158
|
46
|
18.4
|
52
|
O’Sullivan
|
New Zealand
|
2006
|
Osteoporos Int
|
10
|
9Caucasian,1Fijian
|
31
|
|
|
22.0
|
53
|
Bayram
|
Turkey
|
2006
|
Joint Bone Spine
|
1
|
|
37
|
|
|
|
54
|
Allali
|
Morocco
|
2005
|
Clin Rheumatol
|
1
|
|
38
|
|
|
|
55
|
Tran
|
Australia
|
2002
|
Intern Med J
|
3
|
2Caucasian
|
23.22,36
|
157, 170, 160
|
47,48,47
|
19.1,16.6,18.2
|
56
|
Peris
|
Spain
|
2002
|
Clin Exp Rheumatol
|
5
|
|
31
|
155
|
54
|
22.4
|
57
|
Yamaga
|
Japan
|
2000
|
Eur J Obstet Gynecol Reprod Biol
|
1
|
|
25
|
|
|
|
58
|
Gregorio
|
Argentina
|
2000
|
Nutrition
|
3
|
3Caucasian
|
38,33,30
|
155151
|
56,47
|
23.3.20.5
|
59
|
Anai
|
Japan
|
1999
|
J Obstet Gynaecol Res
|
2
|
|
24,30
|
161 155
|
44,47
|
17.0,19.6
|
60
|
Babbitt
|
USA
|
1998
|
J Clin Densitom
|
1
|
|
46
|
175
|
71
|
23.2
|
61
|
Smith
|
England
|
1995
|
QJM-Mon J Assoc Physicians
|
16
|
|
28
|
|
|
|
62
|
Yamamoto
|
Japan
|
1994
|
Calcif Tissue Int
|
5
|
|
30
|
153
|
57
|
24.3
|
63
|
Rillo
|
Argentina
|
1994
|
Clin Rheumatol
|
1
|
|
25
|
|
|
|
64
|
Blanch
|
England
|
1994
|
Br J Rheumatol
|
2
|
2Caucasian
|
31,28
|
|
|
|
65
|
Reid
|
New Zealand
|
1992
|
Clin Endocrinol
|
1
|
Caucasian
|
31
|
|
|
|
Baseline characteristics of enrolled cases
All the enrolled PLO patients aged 19 to 47 years. A total of 191 cases documented the detailed age information with a mean age of 35.7 years. Of the 191 cases, 6 cases over 40 years old accounting for 3.1%, 109 cases over 30 years old accounting for 57.1%, 29 cases under 26 years old accounting for 15.2%. The age distributions are illustrated in Figure.2. The average height of the included cases is 164.2cm, ranged from 144cm to 175cm. The body mass index (BMI) of 46 studies was calculated and documented with a mean value of 22.2kg/m2 ranged from 16.0 kg/m2 to 39.0 kg/m2. The BMI distributions of 98 individuals are showed in Figure.3. The observed data showed that few PLO patients were obese and overweight. Furthermore, race information of 38 cases was documented, which was Caucasians (n = 26), Hans (n = 9), Manchu (n = 1), Fijian (n = 1) and Moroccan (n = 1).
Clinical features
A total of 173 cases had the information on number of pregnancy when vertebral fractures occurred, in whom 149 cases were in primiparity, 19 cases were in the second pregnancy, 4 cases were in the third pregnancy and one case was in the fourth pregnancy. There were 108 cases clearly defined feeding manner, with 102 cases breast-feeding accounting for 94.4%. Up to date, not much literature described the delivery way, in which there were vaginal delivery (n = 11) and cesarean delivery (n = 5).
All the included PLO patients with vertebral fractures were symptomized with back pain. The visual analogue score (VAS) were documented in 17 cases, of which all suffered from mild to severe pain and eight cases (47.1%) complained of severe pain. The earliest time of symptom onset was determined at the 5th month pregnancy, while the latest was at nine months postpartum. Of the 82 cases with definite symptom onset time, 75 cases (91.5%) with back pain occurred during the last three months of pregnancy and the first three months after delivery. The details of distributions are shown in Figure.4.
The risk factors associated with PLO were examined such as drug affecting bone metabolism, pre-partum fractures history, family history of osteoporosis, smoking and abnormal menstruation. A total of 59 patients had provided accurate medication history, of which 17 patients (28.8%) had a history of oral anticoagulants such as heparin, low molecular weight heparin (LMWH) and four patients had a corticosteroids history. Of the 68 cases with pre-partum fractures history documented, 17 (25%) cases were suffered from bone fractures before pregnancy. Regarding to family history of osteoporosis, of all the 172 cases with definite documentation, 57 patients (33.1%) had positive family history of osteoporosis. Smoking status was recorded for 111 cases, in which 24 cases (21.6%) were smokers and ex-smokers. There are less menstruation records in the studies, 4 of 25 cases presenting irregular menses.
The studied articles have indicated variable rates of vertebral fractures. Fracture sites were described in 155 cases with 684 vertebral fractures and the average fracture was 4.4 vertebrae per patient. Most cases were suffered from multiple vertebral fractures with only 14 single segment vertebral fractures. As for specific fracture locations, the three most frequently involved vertebral fractures were L2, L1 and T12 (32.6% of all the fractures). The number and site of fractured vertebrae are shown in Figure.5.
Another important factor is Body mineral density (BMD). BMD values of the enrolled cases were analyzed. Z-scores have been preferable used in the studies as compared to T-scores. The lumbar Z-scores were recorded in 123 cases in mean value of -3.2 ranged from -7.8 to 0, while the hip Z-score were recorded in 122 cases with an average of -2.2 ranged from -5.5 to 0.9. The lumbar T-scores were recorded in 51 cases with an average of -3.6 ranged from -6.5 to -1.3, while the average of the hip T-scores of 47 cases was -2.5 (ranged from -6.5 to -0.2).
Treatment options
Different therapies that have been used in the management of PLO were documented in 108 cases. These therapies included Calcium and vitamin D therapy (n = 7), bisphosphonates (n = 58), teriparatide (n = 24), denosumab (n = 10), calcitonin (n = 6), strontium ranelate (n = 2), simple rehabilitation without medication (n = 2, with mild symptoms) and vertebroplasty (n = 4, with severe symptoms).